KPTI News and Press, Karyopharm Therapeutics Inc. From 03/06/24

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences PR Newswire NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company ...

2024-02-29 18:15:15 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q4 2023 Earnings Call Feb 29, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q4 2023 Earnings C...

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress PR Newswire – Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Co...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

2024-02-25 13:37:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks . Of course, the excitement goes toward both ext...

Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...

2024-02-06 13:12:49 ET More on etc. Madison Square Garden Sports Corp. (MSGS) Q2 2024 Earnings Call Transcript Woori Financial Group Inc. (WF) FY2023 Earnings Call Transcript FSD: The Merger Arbitrage Opportunity Is Quasi Extinguished FAA head says agency is ...

2024-02-05 13:05:53 ET More on Mid-day movers $ stocks. Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade) Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Peraso Inc. (PRSO) Q3 2023 Earnings Ca...

2024-02-05 12:26:46 ET Summary Karyopharm Inc. has entered the realm of undervalued biotech stocks, making it a potential buying opportunity. The company's main drug, selinexor, is currently approved for the management of multiple myeloma and diffuse large B-cell lymphoma. Kar...

2024-01-08 12:35:53 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Karyopharm reports encouraging data for endometrial cancer drug candidate Karyopharm Therapeutics GAAP EPS of -$0.30 misses by...